{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:06Z","timestamp":1790704326129,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.ymgme.2009.10.004","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T15:33:28Z","timestamp":1255534408000},"page":"99-108","source":"Crossref","is-referenced-by-count":139,"title":["Vasculopathy in patients with Fabry disease: Current controversies and research directions"],"prefix":"10.1016","volume":"99","author":[{"given":"S.M.","family":"Rombach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th.B.","family":"Twickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2009.10.004_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s disease: alpha-galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2009.10.004_bib3","unstructured":"R.J. Desnick, Y.A. Ioannou, M.E. Eng, \u03b1-Galactosidase A deficiency: Fabry disease. In: C.R. Scriver, A.L.S.W. Beaudet, D. Valle (Eds.), The metabolic and molecular bases of inherited disease, eighth ed., McGraw-Hill, New York, 2001, pp. 3733\u20133774."},{"key":"10.1016\/j.ymgme.2009.10.004_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgme.2009.10.004_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2009.10.004_bib6","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2009.10.004_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1012423924648","article-title":"Renal pathological changes in Fabry disease","volume":"24","author":"Sessa","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00392-002-0848-5","article-title":"The heart in Anderson Fabry disease","volume":"91","author":"Kampmann","year":"2002","journal-title":"Z. Kardiol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib11","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2009.10.004_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.10.004_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib16","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2009.10.004_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/01913120590951202","article-title":"Ultrastructural study of renal involvement in two females with Anderson\u2013Fabry disease","volume":"29","author":"Tosoni","year":"2005","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5414\/CNP63394","article-title":"Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry\u2019s disease","volume":"63","author":"Svarstad","year":"2005","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications","volume":"43","author":"Meehan","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2009.10.004_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.10.004_bib23","first-page":"206","article-title":"Renal biopsy in Fabry\u2019s disease eight years after successful renal transplantation","volume":"27","author":"Friedlaender","year":"1987","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib24","first-page":"17","article-title":"Clinicopathologic, enzymatic, and genetic features in a case of Fabry\u2019s disease","volume":"104","author":"Burkholder","year":"1980","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jocn.2004.02.002","article-title":"Intermittent claudication\u2014atypical presentation diagnosis and treatment","volume":"11","author":"Taylor","year":"2004","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.ymgme.2009.10.004_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1440-1746.1994.tb01244.x","article-title":"Small bowel ischaemia in Fabry\u2019s disease","volume":"9","author":"Jardine","year":"1994","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2009.10.004_bib28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2169\/internalmedicine.39.646","article-title":"Atypical Fabry\u2019s disease presenting with cholesterol crystal embolization","volume":"39","author":"Shirai","year":"2000","journal-title":"Intern. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00428-008-0653-2","article-title":"Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy","volume":"453","author":"Valbuena","year":"2008","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2009.10.004_bib30","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.humpath.2007.07.001","article-title":"Coronary artery bypass grafting for Fabry\u2019s disease: veins more suitable than arteries?","volume":"38","author":"Chimenti","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-117-3-221","article-title":"Fabry disease: an unusual cause of severe coronary disease in a young man","volume":"117","author":"Fisher","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1440-1789.2008.00883.x","article-title":"An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia","volume":"28","author":"Okeda","year":"2008","journal-title":"Neuropathology"},{"key":"10.1016\/j.ymgme.2009.10.004_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-007-0456-x","article-title":"Postmortem diagnosis of Fabry disease with acromegaly and a unique vasculopathy","volume":"451","author":"Takao","year":"2007","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2009.10.004_bib34","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/brain\/awh546","article-title":"Megadolichobasilar anomaly with thrombosis in a family with Fabry\u2019s disease and a novel mutation in the alpha-galactosidase A gene","volume":"128","author":"Garzuly","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2009.10.004_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","article-title":"Sequelae of storage in Fabry disease\u2014pathology and comparison with other lysosomal storage diseases","volume":"92","author":"Elleder","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2009.10.004_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.54.5.818","article-title":"Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies","volume":"54","author":"Desnick","year":"1976","journal-title":"Circulation."},{"key":"10.1016\/j.ymgme.2009.10.004_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00000478-197906000-00003","article-title":"Fabry\u2019s disease. Primary diagnosis by electron microscopy","volume":"3","author":"Schatzki","year":"1979","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic echocardiographic and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib39","first-page":"660","article-title":"[Postmortem diagnosis of Fabry disease in a female heterozygote leading to the detection of undiagnosed manifest disease in the family]","volume":"138","author":"Hulkova","year":"1999","journal-title":"Cas. Lek. Cesk."},{"key":"10.1016\/j.ymgme.2009.10.004_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"Askari","year":"2007","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2009.10.004_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/01.wnl.0000338566.54190.8a","article-title":"Diagnostic utility of different MRI and MR angiography measures in Fabry disease","volume":"72","author":"Fellgiebel","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.10.004_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry\u2019s disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2009.10.004_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/08035320600618924","article-title":"Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease","volume":"95","author":"Barbey","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2009.10.004_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10545-008-0794-0","article-title":"Intravascular ultrasound assessment of coronary artery involvement in Fabry disease","volume":"31","author":"Kovarnik","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","article-title":"CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy","volume":"27","author":"Jardim","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib47","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson\u2013Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ymgme.2009.10.004_bib48","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/01.CIR.0000062036.35852.01","article-title":"Images in cardiovascular medicine. Myocardial fibrosis in Fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings","volume":"107","author":"Funabashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000047318","article-title":"Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry\u2019s disease. Review of cardiovascular manifestations","volume":"94","author":"Eckart","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.ymgme.2009.10.004_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1253\/jcj.60.315","article-title":"Vasospastic angina in a patient with Fabry\u2019s disease who showed normal coronary angiographic findings","volume":"60","author":"Ogawa","year":"1996","journal-title":"Jpn. Circ. J."},{"key":"10.1016\/j.ymgme.2009.10.004_bib51","first-page":"165","article-title":"Angina pectoris, pathological stress EKG and a normal coronary angiogram","volume":"21","author":"Erdmann","year":"1980","journal-title":"Internist (Berl.)"},{"key":"10.1016\/j.ymgme.2009.10.004_bib52","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-006-0340-x","article-title":"Structural and functional changes in peripheral vasculature of Fabry patients","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jmg.38.9.629","article-title":"Non-invasive evaluation of arterial involvement in patients affected with Fabry disease","volume":"38","author":"Boutouyrie","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2009.10.004_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1651-2227.2002.tb03113.x","article-title":"Arterial remodelling in Fabry disease","volume":"91","author":"Boutouyrie","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2009.10.004_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10545-006-0473-y","article-title":"Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment","volume":"30","author":"Heare","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2261-2-1","article-title":"Arterial wall properties and Womersley flow in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ymgme.2009.10.004_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib58","first-page":"295","article-title":"Non invasive evaluation of endothelial function in patients with Anderson\u2013Fabry disease","volume":"24","author":"Puccio","year":"2005","journal-title":"Int. Angiol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib59","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00415-003-1133-x","article-title":"Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease","volume":"250","author":"Stemper","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib60","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0002-8703(83)90241-7","article-title":"Peripheral hemodynamics in patients with Fabry\u2019s disease","volume":"105","author":"Seino","year":"1983","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ymgme.2009.10.004_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1440-0960.2007.00326.x","article-title":"Fabry disease in a heterozygote presenting as hand ischaemia and painful acroparaesthesia","volume":"48","author":"Martin","year":"2007","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-7120-3-11","article-title":"Reduced coronary flow reserve in Anderson\u2013Fabry disease measured by transthoracic Doppler echocardiography","volume":"3","author":"Dimitrow","year":"2005","journal-title":"Cardiovasc. Ultrasound."},{"key":"10.1016\/j.ymgme.2009.10.004_bib63","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.STR.32.7.1559","article-title":"Enhanced endothelium-dependent vasodilation in Fabry disease","volume":"32","author":"Altarescu","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2009.10.004_bib64","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","volume":"35","author":"Park","year":"2008","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib65","doi-asserted-by":"crossref","first-page":"H1133","DOI":"10.1152\/ajpheart.00929.2008","article-title":"Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse","volume":"296","author":"Park","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib66","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease","volume":"251","author":"Hilz","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib67","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2009.10.004_bib68","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1046\/j.1471-4159.2001.00669.x","article-title":"Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease","volume":"79","author":"Itoh","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2009.10.004_bib69","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1552-6569.2001.tb00051.x","article-title":"Selective arterial distribution of cerebral hyperperfusion in Fabry disease","volume":"11","author":"Moore","year":"2001","journal-title":"J. Neuroimaging."},{"key":"10.1016\/j.ymgme.2009.10.004_bib71","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.10.004_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00868342","article-title":"Stroke in Fabry\u2019s disease","volume":"241","author":"Grewal","year":"1994","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000073054","article-title":"Microembolus detection in four patients with Fabry\u2019s disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms","volume":"50","author":"Ritter","year":"2003","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2009.02.319","article-title":"Thrombosis in Japanese patients with Fabry disease","volume":"283","author":"Utsumi","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgme.2009.10.004_bib75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1755-3768.1994.tb07193.x","article-title":"Central retinal artery occlusion in a patient with Fabry\u2019s disease documented by scanning laser ophthalmoscopy","volume":"72","author":"Andersen","year":"1994","journal-title":"Acta Ophthalmol. (Copenh.)"},{"key":"10.1016\/j.ymgme.2009.10.004_bib76","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archopht.1978.03910050421003","article-title":"Central retinal artery occlusion complicating Fabry\u2019s disease","volume":"96","author":"Sher","year":"1978","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib77","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.STR.0000206442.86238.39","article-title":"Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation","volume":"37","author":"Shen","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2009.10.004_bib78","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis","volume":"14","author":"Eitzman","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10384-008-0572-4","article-title":"A case of anterior ischemic optic neuropathy associated with Fabry\u2019s disease","volume":"52","author":"Kumagai","year":"2008","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib80","first-page":"842","article-title":"Loss of visual acuity due to choroidal ischemia in Fabry\u2019s disease","volume":"26","author":"Guenoun","year":"2003","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00006982-200102000-00024","article-title":"Retinal and choroidal vascular changes in heterozygous Fabry disease","volume":"21","author":"Dantas","year":"2001","journal-title":"Retina"},{"key":"10.1016\/j.ymgme.2009.10.004_bib82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000310318","article-title":"Ischemic optic neuropathy in a female carrier with Fabry\u2019s disease","volume":"205","author":"Abe","year":"1992","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ymgme.2009.10.004_bib83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000309889","article-title":"Several functional and fluorescein fundus angiographic findings in Fabry\u2019s disease","volume":"196","author":"Ohkubo","year":"1988","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ymgme.2009.10.004_bib84","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","article-title":"Endothelial markers and homocysteine in patients with classic Fabry disease","volume":"91","author":"Demuth","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2009.10.004_bib86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.10.004_bib87","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1161\/ATVBAHA.107.143511","article-title":"Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy","volume":"27","author":"Gelderman","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib88","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1093\/ndt\/gfp263","article-title":"Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment","volume":"24","author":"Vedder","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2009.10.004_bib89","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1538-7836.2005.01470.x","article-title":"Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry\u2019s disease","volume":"3","author":"Fedi","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymgme.2009.10.004_bib90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jmri.20162","article-title":"Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study","volume":"20","author":"Moore","year":"2004","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ymgme.2009.10.004_bib91","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease","volume":"67","author":"Kaneski","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.10.004_bib92","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1034\/j.1399-0004.2002.610605.x","article-title":"Endothelial nitric oxide synthase gene polymorphisms in Fabry\u2019s disease","volume":"61","author":"Heltianu","year":"2002","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2009.10.004_bib93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1582-4934.2005.tb00343.x","article-title":"Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction","volume":"9","author":"Heltianu","year":"2005","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ymgme.2009.10.004_bib94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2009.10.004_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1012447102358","article-title":"Natural history of Fabry disease in affected males and obligate carrier females","volume":"24","author":"MacDermot","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib96","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2009.10.004_bib97","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2009.10.004_bib98","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib99","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib100","first-page":"32","article-title":"Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy","volume":"21","author":"Breunig","year":"2008","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib101","doi-asserted-by":"crossref","unstructured":"N. Brakch, O. Dormond, S. Bekri, D. Golshayan, M. Correvon, L. Mazzolai, B. Steinmann, F. Barbey, Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease, Eur. Heart J. (2009). Epub ahead of print.","DOI":"10.1093\/eurheartj\/ehp387"},{"key":"10.1016\/j.ymgme.2009.10.004_bib102","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2009.10.004_bib103","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","article-title":"Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency","volume":"111","author":"Bodary","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib104","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10545-007-0721-9","article-title":"Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.10.004_bib105","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1161\/CIRCULATIONAHA.109.861534","article-title":"Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy","volume":"119","author":"Buja","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib106","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1161\/ATVBAHA.107.159327","article-title":"Role of smooth muscle cells in the initiation and early progression of atherosclerosis","volume":"28","author":"Doran","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","article-title":"Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade","volume":"21","author":"Dandona","year":"2007","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ymgme.2009.10.004_bib108","doi-asserted-by":"crossref","first-page":"H550","DOI":"10.1152\/ajpheart.01176.2008","article-title":"Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint","volume":"296","author":"de Cavanagh","year":"2009","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib109","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1463-1326.2006.00678.x","article-title":"Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance","volume":"10","author":"Brillante","year":"2008","journal-title":"Diab. Obes. Metab."},{"key":"10.1016\/j.ymgme.2009.10.004_bib110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02267818","article-title":"The effect of noradrenaline, angiotensin II and vasopressin on blood flow and sensitivity to heat in capsaicin-treated skin","volume":"8","author":"Drummond","year":"1998","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.ymgme.2009.10.004_bib111","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1681\/ASN.2008111190","article-title":"Decreased nitric oxide bioavailability in a mouse model of Fabry disease","volume":"20","author":"Shu","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2009.10.004_bib112","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00007890-200005270-00022","article-title":"Allograft loss in renal transplant recipients with Fabry\u2019s disease and activated protein C resistance","volume":"69","author":"Friedman","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.ymgme.2009.10.004_bib113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/01.ATV.0000257552.94483.14","article-title":"Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms","volume":"27","author":"McCormick","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209002844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209002844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T23:59:19Z","timestamp":1710633559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719209002844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1096719209002844"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}